Search

CN-121971496-A - Use of lactobacillus reuteri PFL-2501 for improving depression and/or anxiety

CN121971496ACN 121971496 ACN121971496 ACN 121971496ACN-121971496-A

Abstract

The invention belongs to the technical field of biological bactericides and biological medicines, and particularly relates to application of lactobacillus reuteri PFL-2501 in improving depression and/or anxiety. The invention discovers that the lactobacillus reuteri PFL-2501 has remarkable improving effect on depression-like behaviors, exploration and anxiety-related behaviors, can improve the reduction of the level of hippocampal monoamine neurotransmitters of a depressed organism, is specifically embodied to promote the level of 5-HT, DA and NE in hippocampal tissues, inhibits the over-expression of serum pro-inflammatory cytokines, initially confirms that the serum pro-inflammatory cytokines play a role through a neurotransmitter steady-inflammatory regulation pathway, covers a dual core pathway of depression onset, has more definite curative effect and no side effect risk, and lays a research foundation for the development of subsequent antidepressant products.

Inventors

  • ZHU FENG
  • HAO DANDAN
  • WANG YIYANG
  • Jia Jiangyuan

Assignees

  • 西安交通大学医学院第一附属医院
  • 宁波菌佑医疗科技发展有限公司

Dates

Publication Date
20260505
Application Date
20260305

Claims (10)

  1. 1. Use of lactobacillus reuteri (Limosilactobacillus reuteri) PFL-2501, said lactobacillus reuteri PFL-2501 having a preservation number of CGMCC No.35503, for the manufacture of a product for improving depression and/or anxiety.
  2. 2. The application of the microbial inoculum containing the lactobacillus reuteri PFL-2501 in preparing products for improving depression and/or anxiety, wherein the preservation number of the lactobacillus reuteri PFL-2501 is CGMCC No.35503.
  3. 3. The use according to claim 2, wherein the bacterial agent comprises a bacterial liquid of lactobacillus reuteri PFL-2501.
  4. 4. Use according to claim 2 or 3, wherein the dosage form of the bacterial agent comprises a liquid or a solid agent.
  5. 5. The use according to claim 2, wherein when lactobacillus reuteri PFL-2501 cells are included in the microbial inoculum, the effective viable bacteria concentration of lactobacillus reuteri PFL-2501 is not less than 1 x 10 8 CFU/mL.
  6. 6. The use according to claim 2, wherein the preparation method of the microbial inoculum comprises the steps of inoculating lactobacillus reuteri PFL-2501 into a culture medium for fermentation culture or expansion culture, and obtaining the microbial inoculum.
  7. 7. The use according to claim 1 or any one of claims 2 to 6, wherein the product comprises a pharmaceutical product.
  8. 8. The use of claim 7, wherein the pharmaceutical product comprises a pharmaceutical product for treating depression.
  9. 9. The use of claim 8, wherein the treatment of depression comprises at least one of improving depression-like behavior, restoring neurotransmitter homeostasis, and inhibiting inflammatory responses.
  10. 10. A product for improving depression and/or anxiety, characterized in that the product comprises a bacterial agent comprising lactobacillus reuteri PFL-2501 or a derivative of lactobacillus reuteri PFL-2501 and an adjunct; The preservation number of the lactobacillus reuteri PFL-2501 is CGMCC No.35503.

Description

Use of lactobacillus reuteri PFL-2501 for improving depression and/or anxiety Technical Field The invention belongs to the technical field of biological bactericides and biological medicines, and particularly relates to application of lactobacillus reuteri PFL-2501 in improving depression and/or anxiety. Background Depression is a common mental disorder manifested by long-term depression, dysphoria, attention loss, etc., and is the result of the combined actions of social, psychological and biological factors. Depending on the severity and type of depressive episode in the patient, the treatment means include psychotherapy and medication or a combination of both. The types of antidepressants commonly used at present are monoamine oxidase inhibitors, selective serotonin reuptake inhibitors and the like, and the drugs can improve the emotion and behavior of individuals by affecting neurotransmitters in the brain, so as to achieve the aim of preventing or improving the symptoms of depression. However, the effect of antidepressant drugs in treating depression varies from individual to individual, and only one third of the individuals have sustained therapeutic effects and cause uncomfortable reactions such as headache, nausea and vomiting, constipation, etc. In recent years, the bi-directional communication between the intestinal tract and the brain has been widely studied, and the composition of the intestinal flora has been related to changes in host physiological regulation, and changes in bacteria in the gastrointestinal tract, including commensal bacteria, probiotics and pathogenic bacteria, affect brain function. Several studies have shown that alterations in intestinal flora composition are important in connection with the occurrence of mental disorders such as depression and anxiety. The intestinal flora is able to interact with the brain by modulating inflammatory responses, neurotransmitters, hypothalamic-pituitary-adrenal axis, etc. and has a positive impact on the amelioration of depression. In some studies known to the inventors, supplementation with specific probiotics or faecal fungus transplants has been shown to improve anxiety-depression-like behaviour induced by disturbed intestinal flora. Lactobacillus reuteri is one of the important members of the genus lactobacillus, and is widely found in the intestinal tract of humans and various animals, milk and fermented foods, and belongs to facultative anaerobes. The existing research on the strain focuses on the traditional physiological effects of regulating the balance of intestinal flora, improving the functions of the digestive system and the like, and the action mechanism and the application value of the strain in the directions of immunoregulation, metabolic regulation, neuroprotection and the like still need to be further mined and verified. Thus, the isolation and identification of novel lactobacillus reuteri with a clear improvement in anxiety-depression phenotypic activity is urgent to elucidate the efficacy and mechanism of action. Disclosure of Invention The invention aims to provide application of lactobacillus reuteri PFL-2501 in improving depression and/or anxiety, wherein the lactobacillus reuteri PFL-2501 can effectively improve depression and anxiety and has remarkable effect. The invention provides application of lactobacillus reuteri PFL-2501 in preparing a product for improving depression and/or anxiety, wherein the preservation number of the lactobacillus reuteri PFL-2501 is CGMCC No.35503. The invention also provides application of the microbial inoculum containing the lactobacillus reuteri PFL-2501 in preparing products for improving depression and/or anxiety, wherein the preservation number of the lactobacillus reuteri PFL-2501 is CGMCC No.35503. Preferably, the microbial inoculum comprises lactobacillus reuteri PFL-2501 bacterial solution. Preferably, the dosage form of the microbial agent comprises a liquid agent or a solid agent. Preferably, when the bacterial agent comprises lactobacillus reuteri PFL-2501 bacterial, the effective viable bacteria concentration of the lactobacillus reuteri PFL-2501 is more than or equal to 1 multiplied by 10 8 CFU/mL. Preferably, the preparation method of the microbial inoculum comprises the following steps of inoculating lactobacillus reuteri PFL-2501 into a culture medium for fermentation culture or expansion culture to obtain the microbial inoculum. Preferably, the product comprises a pharmaceutical product. Preferably, the pharmaceutical product comprises a pharmaceutical product for treating depression. Preferably, the treating depression includes at least one of improving depression-like behavior, restoring neurotransmitter homeostasis, and inhibiting inflammatory responses. The invention also provides a product for improving depression and/or anxiety, which comprises a microbial inoculum and auxiliary materials containing lactobacillus reuteri PFL-2501 or lactobacillus reuteri PFL-